Molbio Diagnostics returned to profitability in the June 2026 quarter, reporting a net profit of ₹58.7 crore against a loss in the year-ago period. Revenue rose more than four-fold to ₹408.4 crore, while EBITDA turned positive at ₹100.58 crore, reflecting the recently listed diagnostics company’s strengthening financial performance post-IPO.